Therapy-related myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML) are serious complications of chemotherapy and radiotherapy for cancer. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be associated with an increased incidence of these complications. The frequency of t-MDS/AML after ASCT for breast cancer is uncertain. We reviewed our database of 379 consecutive breast cancer ASCT patients treated with alkylatorbased chemotherapy, followed for a median of 1.52 years (range 0-8.97), with a median survival of 6.16 years. Three patients have developed tMDS/AML. The probability of developing this complication at 5 years is 0.032 in our series. We have used pathologic, cytogenetic and molecular methods to evaluate which portions of therapy may have predisposed to the development of this complication. Cytogenetic abnormalities were not found in the stem cell harvests of these patients by metaphase analysis or by fluorescence in situ hybridization (FISH). One patient demonstrated a clonal X chromosome inactivation pattern in her stem cell harvest, indicating pre-transplant chemotherapy may have been responsible for the development of her leukemia. As two of our patients developed this complication at greater than 4 years post-transplant, the number of cases may increase with longer follow-up. While the incidence appears to be low, further prospective and retrospective analysis will be necessary to determine which portions of therapy predispose to the development of t-MDS/AML in patients undergoing ASCT for treatment of breast cancer.
Introduction
Autologous stem cell transplantation following high-dose chemo-radiotherapy is being investigated as treatment for high risk and advanced breast cancer. In analyzing the risks and benefits of ASCT, the occurrence of therapy-related myelodysplastic syndrome and acute leukemia related to this procedure, is an important consideration. Using standard-dose chemotherapy, exposure to alkylating agents has been associated with t-MDS/AML having abnormalities of chromosomes 5 and 7, 1 and the use of topoisomerase II inhibitors, including doxorubicin, has been associated with t-MDS/AML containing translocations of chromosome 11q23, the MLL gene. 2 The median time from exposure to onset of t-MDS/AML is 5 to 7 years after alkylating agents, but may be measured in months after topoisomerase II inhibitors. Therapy-related leukemias are in general refractory to conventional treatment and associated with poor survival, with the possible exception of acute promyelocytic leukemias. 3 As recently reviewed by PedersenBjergaard et al, 4 survival after t-MDS/AML occurring posttransplant is estimated to be 6 months.
The majority of studies of t-MDS/AML post-transplant have been in patients treated for lymphoma. [5] [6] [7] [8] [9] [10] [11] [12] [13] After stem cell transplantation for lymphomas, there appears to be a substantial risk of t-MDS and t-AML, reaching over 15-20% at 5 to 6 years. 7,10.11,13,14 However, in patients with non-Hodgkin's lymphoma, the risk of t-MDS/AML with conventional therapy may be quite high, related to the number of prior conventional treatments and to the extensive use of both alkylating agents and topoisomerase inhibitors in common chemotherapy regimens. At least one large study of patients with Hodgkin's disease suggested that ASCT was not associated with any increased risk of t-AML as compared with patients treated to a similar extent with conventional chemotherapy. 15 For lymphoma ASCT, age and the extent of prior alkylating agent exposure appear to be clear risk factors for the development of t-MDS/AML. Radiation in the conditioning regimen, 6 etoposide in the mobilization regimen, 8 and fludarabine as a prior lymphoma treatment, 14 may also be risk factors. A higher risk has also been associated with the use of peripheral blood stem cells harvested using conditioning chemotherapy and cytokines, as compared with unstimulated bone marrow harvests (reviewed in Ref. 4) .
The incidence of t-MDS/AML after conventional therapy for breast cancer appears to be low. Estimated incidence ranges from 0.06% with standard adjuvant chemotherapy to 0.58% with combined modality therapy. [16] [17] [18] [19] Various relapse chemotherapy regimens provide an unknown additional risk. The incidence of this complication after autologous stem cell transplantation for breast cancer appears to be lower than for lymphoma, although the number of patients currently at risk is smaller and length of follow-up for these patients is shorter. 20, 21 We report three patients who have developed t-MDS/AML from our database of 379 consecutive breast cancer patients who have undergone ASCT with alkylator-based chemotherapy from June 1991 to March 2000. We have used pathologic evaluation, conventional cytogenetics, fluorescence in situ hybridization (FISH) and human androgen receptor alpha (HUMARA) X-chromosome inactivation assay in an attempt to determine which portion(s) of therapy may have been responsible for the development of t-MDS/AML in our patients.
Materials and methods

Patient data
Informed consent for stem cell transplantation and research analyses on harvested stem samples is obtained in accordance with the Columbia University IRB approved CAMP 001 and 007 protocols. Patients are evaluated prior to transplant, and receive their transplant and 1 month post-transplant evaluation at our institution. Further follow-up is obtained at 3, 6 and 12 months post-transplant and at yearly intervals there-after. Any patient with persistent cytopenias is evaluated by bone marrow aspiration and biopsy, and those results are confirmed by our hematopathologist. Further clinical data are obtained from retrospective chart review and contact with referring physicians.
Cell samples and DNA preparation
Stem cell samples pre-transplant and peripheral blood or bone marrow samples pre-and post-transplant were obtained according to the IRB approved protocols. Peripheral blood was separated into lymphocyte and neutrophil components using neutrophil isolation media (Cardinal Products, Santa Fe, NM, USA). Lymphocytes were used as an internal control. Ficoll/Hypaque gradient separation (Sigma, St Louis, MO, USA) was used for all other separation. Stem cell samples were collected in ACD-A solution, frozen at −90°C at a 1:1 concentration in 5% dimethylsulfoxide, 6% hydroxyethylmethyl starch, 4% human serum albumin and used directly upon thawing. Genomic DNA was prepared by standard techniques using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA). Buccal mucosal DNA was prepared from swabs using protein lysis buffer (Lifecodes, Stamford, CT, USA).
HUMARA assay
The human androgen receptor assay is a polymerase chain reaction (PCR) for XCIP (X-chromosome inactivation patterns) (reviewed in Ref. 22 ). The HUMARA region on the X-chromosome contains a differential number of trinucleotide repeats, having >90% heterozygosity in females. Using methylationsensitive enzymes prior to PCR, one can distinguish the percentage of each X chromosome expressed within a population of cells, in the majority of female subjects. 23, 24 Skewed patterns of inactivation or changes over time in the pattern of inactivation imply clonal, hence potentially malignant, growth. This assay has been used to analyze the clonal origin of a number of hematopoietic disorders. [25] [26] [27] [28] DNA samples (10 ng-1 g) were subjected to PCR with fluoroscein-labeled primers (Genosys, Woodlands, TX, USA), using previously published primers: 5ЈTCCAGAATCTGT TCCAGAGCGTGC3Ј; 5ЈGCTGTGAAGGTTGCGGTTCCT CAT3Ј; and a modification of previously published conditions. 29 Analysis was performed on an ABI Automated Sequencer and analyzed for fluorescence intensity using Genescan software (ABI Prism; Perkin-Elmer, Norwalk, CT, USA).
For each sample, a corrected ratio was calculated dividing the ratio (allele1/allele2) of the digested sample by the ratio of the undigested sample. A final clonality ratio was determined by dividing the corrected ratio of the lesional DNA by that of the control DNA (lymphocytes, buccal cells), to account for unequal lyonization and analyzed in triplicate. As described previously 22, 30 hematopoietic skewing was defined as allele ratios greater than 1:1 after correction for baseline skewing, while clonal skewing has been defined as ratios greater than 3:1.
Karyotype and fluoresence in situ hybridization (FISH) analysis
Karyotype analysis was performed by conventional G-banding techniques. Interphase FISH was performed on previously harvested and cryopreserved stem cell samples. FISH was performed using a double color chromosome 5 locus specific probe EGR1 (5q31) (spectrum orange)/D5S23 (5p15) (spectrum green) obtained from Vysis (Downer's Grove, IL, USA), and a chromosome 11 locus-specific MLL (11q23) probe labeled with digoxigenin (Ventana Medical Systems, Tucson, AZ, USA). The FISH signals were scored and processed on an Applied Imaging Cytovision work station.
Pathologic evaluation
Formalin fixed, conventionally processed bone marrow specimens obtained before and after marrow transplant were examined by light microscopy. Immunohistochemical stains with CD34 (Clone QBEND10; Novocastra, Newcastle Upon Tyne, UK), myeloperoxidase (polyclonal; Dako, Carpinteria, CA, USA), and CD68 (KP-1, Dako) were performed according to published methods.
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Statistical analysis
Kaplan-Meier estimates were used to obtain the probabilities of survival and incidence of t-MDS/AML among the patients studied, along with 95% confidence intervals. In performing the calculations for incidence of t-MDS/AML, patients who died without an event were considered censored at the time of death.
Results
Patient characteristics
Clinical information was retrospectively reviewed on 379 consecutive patients with breast cancer who underwent ASCT using alkylator-based high-dose chemotherapy in Columbia University's transplantation program. We report three patients in our breast cancer transplant program who developed t-MDS/AML after high-dose chemotherapy and ASCT (Table 1 ). Our patients were followed for a median of 1.52 years (range 0-8.97). Median survival is 6.16 years, with 84% of subjects ) and tamoxifen for 6 months with response. Peripheral blood stem cells were harvested after 1.5 g/m 2 cyclophosphamide and granulocyte colonystimulating factor (G-CSF). She required two leukaphereses to reach an estimated cell dose of 2.9 × 10 6 mononuclear cells/kg (MNC/kg). Bone marrow (0.5 × 10 6 MNC/kg) was also collected. The patient was transplanted using CTCb conditioning chemotherapy (cyclophosphamide 6 g/m 2 , thiotepa 500 mg/m 2 , carboplatin 800 mg/m 2 ). Relapse of disease occurred in the lumbo-sacral spine 4 years post-transplant and radiation therapy was administered. Post radiation she had significant pancytopenia which did not resolve and a bone marrow biopsy was performed at approximately 4.38 years post transplant, and RAEB was diagnosed. She refused further therapy and died approximately 1 year later.
The pre-transplant bilateral biopsies and aspirates showed focally hypocellular (on average 40%) marrow with decreased myelopoiesis, relative erythroid hyperplasia, and active maturing megakaryopoiesis explained on the basis of recent chemotherapy. No evidence of myelodysplasia or metastatic carcinoma was seen in this specimen. The post-transplant specimen showed increased cellularity (on average 65%) due to increased dysplastic erythropoiesis, left-shifted myelopoiesis with 15% blasts, dysplastic micromegakaryocytes and diffuse mild reticulin fibrosis. The immunohistochemical stains with CD34, myeloperoxidase and CD68 (KP-1) showed focal positivity in the blasts indicating refractory anemia with excess of blasts. Cytogenetic analysis on three consequtive bone marrow aspirates revealed a complex karyotype: 45, XX, del(3)(p11;p14) der 5t(5;10) (q13;q11), del (6) (p23) ,i(8)(q10), −10, t(17;22)(q13;q11). Retrospective analysis of the stem cell harvest by FISH on 235 interphase cells revealed no evidence of chromosome 5 abnormalities using the EGR1 probe.
DNA for HUMARA analysis was prepared from specimens of stem cell harvest, buccal mucosa, and separated peripheral blood at the time of t-MDS diagnosis. The alleles differed by a single trinucleotide repeat. Results of fluorescence intensity analysis of the two alleles are shown (Figure 1a) . The X-inactivation ratio of the stem cell harvest specimen showed skewing with a ratio of 2.54 after correction using the lymphocyte/buccal mucosal control. The neutrophils from peripheral blood taken at the time of MDS diagnosis showed, as might be expected, a clonal X-inactivation ratio of 3.15.
Patient 2 presented with AML and leukemia cutis, 5 months post-transplant. The patient initially presented at age 34 years with node negative infiltrating ductal carcinoma. She underwent lumpectomy followed by local radiation therapy. She was well for over 15 years, when she underwent TAH/BSO for a poorly differentiated adenocarcinoma of the endometrium, metastatic to the ovary (stage IIIA). Surgery was followed by adjuvant pelvic external beam radiation. Within the year she was diagnosed with high risk stage II breast cancer, a 1.5-cm poorly differentiated, invasive ductal cancer with 34/36 nodes positive. She underwent lumpectomy followed by six cycles of standard CAF every 3 weeks. This was
Leukemia
Figure 1
HUMARA clonality ratios as determined by PCR. (a) Skew ratios for patient 1. (b) Skew ratios for patient 2. Buccal, lymphocyte, neutrophil and stem cell aliquots, respectively, with and without HpaII digestion.
followed by a cycle of paclitaxel for stem cell harvesting (175 mg/m 2 with G-CSF). She required six leukaphereses to reach a cell dose of 23.25 × 10 6 MNC/kg. She then received high-dose therapy with standard CTCb followed by stem cell infusion, engrafting by day 10. She received adjuvant breast radiotherapy post-transplant and was placed on tamoxifen. Five months post-transplant the patient presented with a diffuse skin rash. Blood count showed a white cell count of 3.6, hemoglobin of 10.8, platelets of 56 000. Skin biopsy was consistent with acute monocytic leukemia. A subsequent bone marrow biopsy confirmed this diagnosis. She was treated with Mylotarg (Wyeth), but died of progressive leukemia.
The pre-transplant bilateral biopsies and aspirates showed borderline hypocellular (35%) marrow with focally decreased myelopoiesis, relatively increased erythropoiesis, and active maturing megakaryopoiesis with occasional dysplastic forms explained on the basis of recent chemotherapy. No evidence of metastatic carcinoma was seen in this specimen. The posttransplant marrow specimen showed an increased cellularity (55%), left-shifted myelopoiesis, with 25% monocytoid blasts. The megakaryocytes showed severe dysplasia with numerous micromegakaryocytes and diffuse mild reticulin fibrosis. Immunohistochemistry showed positive staining in the blasts with myeloperoxidase and CD68, diagnostic of a myelodysplastic syndrome with transformation to AML-M5. A second biopsy a month later showed a higher proportion of blasts (approximately 50%) with a monocytic immunophenotype by flow cytometry (CD14, CD11c, CD13, CD33, and negative with CD34) diagnostic of therapy-related acute non-lymphocytic leukemia (AML-M5). Cytogenetic analysis at the time of MDS diagnosis revealed: 46, XX, inv (11) (p15q23) {16}/46, XX {4}. This chromosome 11 abnormality was not recognized by the FISH probe specific for the MLL (11q23) translocation after analyzing 200 interphase cells. Metaphase analysis of the previously cryopreserved specimen was unsuccessful.
DNA for HUMARA analysis was prepared from specimens of stem cell harvest, buccal mucosa and peripheral blood separated at the time of AML diagnosis. The alleles differed by a single trinucleotide repeat. Of interest, the stem cell harvest specimen showed no evidence of clonal skewing by HUM-ARA analysis, despite the relatively short period between stem cell reinfusion and development of leukemia (Figure 1b) . The lymphocyte control showed clonal skewing while buccal cells did not, suggesting contamination of the lymphocyte preparation with myeloblasts in the neutrophil-separated specimen.
Patient 3 presented with myelodysplasia 4.5 years post transplant. The patient initially presented at age 51 years with stage II breast cancer 4 years prior to transplant. After mastectomy she received cyclophosphamide, methotrexate and 5FU in standard doses followed by tamoxifen. Disease recurred 3.5 years later in supraclavicular lymph nodes. She received seven cycles of CAF and was harvested after her sixth cycle achieving a cell count of 1.59 × 10 6 MNC/kg with two leukaphereses. A bone marrow harvest was also performed with a cell dose of 0.44 × 10 6 MNC/kg. High-dose therapy was given with CTCb. She engrafted on day 14. She was without evidence of disease until 4.6 years post transplant when she had pancytopenia. Bone marrow performed by her local oncologist reported refractory anemia with less than 10% blasts. Cytogenetics revealed an 11q23 translocation (46, XX, t(9;11)(p22;q23)). The patient received supportive treatment with transfusion and cytokines, and died 6.5 years posttransplant.
The pre-transplant biopsy and aspirate were normocellular, with normal maturation and no evidence of myelodysplasia or metastatic carcinoma. No biopsy material is available for analysis from the specimen diagnostic of MDS/AML for HUM-ARA analysis. FISH performed on cryopreserved stem cell harvest found no evidence of an 11q23 abnormality using the MLL probe.
Statistical analysis
Eighteen percent of our 379 patients had follow-up greater than 4.6 years, (the time when our third patient developed MDS). Actuarial survival at 4.6 years is 0.542 and overall survival is plotted in Figure 2 . Median follow-up is 1.52 years, Figure 2 Overall survival. . with a range of 0-8.97. The rate of MDS/AML at 5 years is 0.032 (95% CI: 0-0.071) estimated from the Kaplan-Meier plot. Time to MDS/AML is plotted in Figure 3 . These data suggest that with longer follow-up, further cases may be seen, and that a significant percentage of these high-risk patients may be dying of their underlying breast cancer prior to the time of risk for development of MDS/AML.
Retrospective clonality analysis
To determine whether skewed XCIPs are more frequent than the clinical presentation of MDS, we attempted to retrospectively analyze clonality on the 50 longest treated patients on our protocols. We were able to obtain seven current blood samples for lymphocyte preparation. None of these patients had clonal skewing in their cryopreserved harvest specimens by HUMARA analysis as compared with current lymphocyte specimens, with skew ratios ranging from 0.72 to 1.45.
Discussion
Three of our 379 consecutive breast cancer stem cell transplant patients have developed t-MDS/AML since we initiated our program for stem cell transplant for breast cancer in 1991. We have used a variety of techniques to determine which portion(s) of therapy may have been responsible for the development of these secondary malignancies. Pathologic evaluation of the bone marrow was performed on all patients prior to stem cell harvesting. Review of our three patients who developed t-MDS/AML confirmed the lack of significant dysplasia prior to stem cell harvesting. While cytogenetic abnormalities were present in all three of our patients at the time of diagnosis of t-MDS/AML, we were unable to detect these abnormalities in cryopreserved aliquots of their stem cell harvests. In our first patient, the skewed HUMARA results in the stem cell aliquot suggest that clonal abnormalities were present prior to transplant despite lack of clonal abnormalities of the 5q31 regioin by FISH. In patient 2 the latency between transplant and the development of t-MDS/AML was so brief that it is unlikely that high-dose therapy was responsible. Rather, her heavy pre-treatment with alkylating agents and topoisomerase inhibitors for both breast and ovarian cancer
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Time to MDS/AML.
may have been responsible. The abnormalities in chromosome 11 at diagnosis were not detected using the standard MLL probe and so could not be routinely evaluated in her stem cells. The third patient also had an 11q23 translocation at MDS diagnosis, which was not detected on retrospective analysis of her cryopreserved stem cell harvest by cytogenetics or FISH. These results suggest either that the cytogenetic abnormalities developed post-transplant, or that these tests are limited by both sensitivity and specificity using previously cryopreserved stem cell aliquots. In a study from Duke University Marrow Program, 33 harvested bone marrows were evaluated by conventional cytogenetics retrospectively in four of five patients who developed t-MDS/AML after autologous bone marrow transplantation and had no detectable abnormalities. Pre-transplant specimens on patients with t-MDS/AML and chromosomal translocations were evaluated by FISH in a larger multi-center study, which included four breast cancer patients. In all four of these patients FISH was able to detect, in pre-transplant specimens, abnormalities seen post-transplant. Our results suggest FISH is imperfect as a single method of testing. A recent study using triple FISH techniques 34 provides a highly informative panel of FISH markers for analysis of therapy-related chromosomal abnormalities. A prospective use of this type of FISH panel may overcome some of the limitations seen with cytogenetic studies including our own.
The predictive value of the HUMARA clonality assay for the onset of t-MDS/AML has been evaluated in non-Hodgkin's lymphoma patients after autologous stem cell transplant. 30 Clonal hematopoiesis, as defined by this assay, correlated with the development of t-MDS/AML. Retrospective analysis found that a significant number of lymphoma patients had a skewed HUMARA analysis prior to transplant. While constitutive skewing of the two HUMARA alleles with increasing age 35 may mimic clonality, and variability in methylation patterns may affect the ability to perform the assay on some patients, 36 with appropriate tissue controls (lymphocyte, buccal mucosa) this assay may be informative in a large number of patients. 30 In our experiments using controls for preferential PCR amplification and selective lyonization, patient 1 had a skewed ratio in her stem cell harvest. In the second patient with a very short latency between transplant and the onset of t-MDS/AML, we were surprised to find the stem cell harvest showed no skewed ratio. Clonality analysis using the HUM-ARA assay is not sensitive to small clonal populations. 28 Whether sensitivity can be increased by using ratios of less than 3:1 along with changes in the X-inactivation ratio over time remains to be analyzed in a prospective fashion. Ideally, such a test could be used to screen patients prior to transplantation, and allow consideration of alternatives for treatment. In their lymphoma study, Mach-Pascual et al 30 found clonal analyses (HUMARA ratios of Ն3:1) in 3% of 104 patients. Additionally, a skewed ratio (Ͼ1 but Ͻ3) was present in 20%. Over the time period tested, three of 18 patients with skewed X-inactivation developed clonal hematopoiesis. A clonal HUMARA assay was found to be predictive for developing t-MDS/AML at a probability level of 0.004. In our first patient, the skewed HUMARA result in the stem cell aliquot suggests that clonal abnormalities were present prior to transplant despite normal metaphase cytogenetics and FISH.
Several lines of evidence support the concept that pretransplant therapy may put breast cancer patients at risk for t-MDS/AML post transplant. A higher incidence of t-MDS in breast cancer has been linked to combined radiation and Leukemia alkylating agents, 37 and the use of more leukemogenic alkylating agents such as melphalan. 18 Two recent reports provide evidence that more aggressive adjuvant therapy may be responsible for an increased risk of t-MDS/AML. An update from the National Surgical Adjuvant Breast and Bowel Project B-25 protocol, 38 in which dose-intense doxorubicin and cyclophosphamide were given as adjuvant treatment, led to a cumulative incidence of AML or MDS of 0.87%. Seventeen patients developed AML or MDS out of 2548 women treated between April 1992 and February 1994. Three of the six patients who presented early after treatment had 11q23 abnormalities, consistent with topoisomerase II inhibitor therapy (doxorubicin). Several of the later cases had abnormalities of chromosomes 5 and 7, more typical of alkylating agent (cyclophosphamide) induced t-MDS/AML. Data presented by the Scandinavian Breast Cancer study group 39 also provides evidence that patients treated with dose intense 'tailored' FEC chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide) had a higher than expected incidence of t-MDS/AML (six AML, three MDS) occurring in 251 patients at risk with a median follow-up of 34 months as compared with no cases of t-MDS/AML in 274 patients treated with standard FEC for three cycles followed by CTCb and stem cell transplant. The Cote d'Or registry 40, 41 has also reported an increased incidence of t-AML among their 3093 patients with breast cancer. Ten cases of acute leukemia occurred and the incidence was significantly increased in those patients treated with combined modality therapy and was associated in a dose-dependent fashion with the prior use of mitoxantrone-based regimens.
In conclusion, whether the application of high-dose therapy and or subsequent treatment hastens the onset of t-MDS/AML is an important question that cannot yet be answered by our studies. Data from our large population of breast cancer patients confirm previous reports that the incidence of MDS/AML after stem cell transplant appears to be small. Kaplan-Meier estimates of the 5-year rate of MDS/AML in our patients is 0.032. Given the long latency period for the development of MDS seen after alkylating agent chemotherapy, with longer follow-up and improved survival, we may see further cases of t-MDS/AML. The limitations of this approach emphasize the need for prospective analysis of patients prior to and after autologous transplant using a multifaceted approach including pathologic analysis, cytogenetics, FISH and XCIP analysis to determine t-MDS/AML risk for patients with breast cancer.
